Aclaris Therapeutics to Present at Upcoming Investor Conferences
12 nov. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that...
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
07 nov. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflammatory Development PipelineDivested RHOFADE® (oxymetazoline hydrochloride) cream, 1%Repaid $30 Million Term...
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
31 oct. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will...
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
24 oct. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpointHighly...
Aclaris Therapeutics Announces Divestiture of RHOFADE®
10 oct. 2019 16h02 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has...
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
08 oct. 2019 17h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the...
Aclaris Therapeutics to Hold R&D Day
17 sept. 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will...
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
16 sept. 2019 16h15 HE
|
Aclaris Therapeutics, Inc.
Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29Highly statistically significant results on all secondary efficacy endpointsWART-302...
Aclaris Therapeutics Announces New Strategic Direction
05 sept. 2019 08h30 HE
|
Aclaris Therapeutics, Inc.
Completion of Strategic Review and Refocusing of Resources on Immuno-Inflammatory Development PipelineActively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream,...
Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
08 août 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
Undertaking strategic review of commercial and R&D assetsIND for ATI-450, an investigational compound and oral MK2 inhibitor, allowed by the FDA in May 2019, and first patient dosed in Phase 1...